JB Chemicals & Pharmaceuticals Ltd said in a filing that it has received EIR for newly set up and commissioned solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat.
“Company is in receipt of the Establishment Inspection Report (EIR) from the USFDA for the Company's newly set up and commissioned solid oral dosage forms formulations manufacturing facility at Panoli, Gujarat. The USFDA issues an EIR to the Company when an inspection is satisfactorily "closed", JB Chemicals said.
The company said the inspection was carried out from June 24-28, 2019. At the end of the inspection, "No Objectionable Observation" was found and no Form 483 was issued.
This new facility known as (T20) has already been approved by the other regulatory authorities like EU, TGA-Australia, Saphra-South Africa. This is another facility in addition to the one already approved by USFDA.
The new facility will augment the Company's manufacturing capacity for regulated markets like USA, EU, Australia and South Africa, it added.
The stock is currently trading at Rs588.70, up by Rs11.75 or 2.04% from its previous closing of Rs576.95 on the BSE.
The scrip opened at Rs582.85 and has touched a high and low of Rs591.40 and Rs572.90 respectively.
For Quick Trial – 8871888787
or mail us here - support@researchicon.com
or visit - http://www.researchicon.com/free-trial
Post a Comment